Replies to post #334437 on Bioelectronics Corp (BIEL)

[G-star]

Dr.Ambika Choudari on LinkedIn

In a world where medical devices are transforming healthcare and saving lives daily, ensuring regulatory compliance is crucial to keep these innovations accessible to those who need them most!

A bit late in sharing this, but I’m thrilled to share that I had the amazing opportunity to lead a project at BioElectronics Corporation focused on the development of a Standard Operating Procedure (SOP) for Unique Device Identification (UDI), a critical piece in transitioning our Class IIa medical devices from MDD (Medical Devices Directive) to MDR (Medical Devices Regulation) in the EU.

This transition marks a critical shift in EU regulations, with MDR introducing more stringent requirements for medical devices to enhance transparency, traceability, and patient safety. While our devices currently hold "legacy device" status under MDD until 2028, the UDI SOP ensures we are prepared for future MDR certification, ensuring that our life-enhancing products continue to reach patients worldwide post-2028.

Project Highlights:
•Developed a robust UDI framework, covering key components like UDI-DI, UDI-PI, and EUDAMED integration.
•Aligned with MDR requirements, ensuring our QMS and technical documents are future-ready for Notified Body review
•Set the company on a path for uninterrupted market access beyond 2028, safeguarding patient care globally.

It’s been an incredible experience to contribute to something so impactful and essential for the future of healthcare. I’m looking forward to more opportunities where innovation meets compliance!
Also, I would like to thank Zoya Atiq for her immense support and guidance.

hashtag#MedicalDevices hashtag#UDI hashtag#MDRCompliance hashtag#HealthcareInnovation hashtag#SOPDevelopment hashtag#PatientSafety hashtag#EUDAMED hashtag#MilestoneAchieved hashtag#RegulatoryAffairs

[GetSeriousOK]

That's all about a class project done by a Regulatory Affairs graduate student. She did all the work. Looks good on her resume -- "Project Lead at Bioelectronics Corp."

She's not a Doctor -- she's a pharmacist. She's a "PharmD graduate currently pursuing Master of Science in Regulatory Affairs at Northeastern University while working as a Regulatory Affairs intern with a relentless commitment to advancing global healthcare standards."

BIEL didn't do anything. Giving BIEL credit for "checking all the boxes" as a result of this class project is like giving BIEL credit for Ilfeld's research.

Here's what the grad student said on her resume:

* Spearheaded the creation of a comprehensive Standard Operating Procedure (SOP) for Unique Device Identification (UDI) tailored to Class IIa medical devices in compliance with upcoming EU MDR regulations.

• Facilitated the transition of medical devices from MDD (Medical Devices Directive) to MDR (Medical Devices Regulation), ensuring alignment with enhanced regulatory requirements and maintaining "legacy device" status until 2028.

BIEL's devices already had "legacy device status until 2028." This is resume business-speak. It makes it sound like there's nothing left to be done in order for ActiPatch and RecoveryRx to meet all the MDR requirements in 2028. Did you read those requirements?